Invokamet is a prescription medication used to treat type 2 diabetes [1]. It combines two active ingredients: canagliflozin and metformin [1].
What are the ingredients in Invokamet?
Invokamet contains canagliflozin, which belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors, and metformin, a biguanide [1]. Canagliflozin works by helping the kidneys remove excess glucose from the bloodstream, while metformin reduces the amount of glucose produced by the liver and increases the sensitivity of muscles to insulin [1].
How does Invokamet work to lower blood sugar?
The combination of canagliflozin and metformin targets multiple pathways to control blood glucose levels. Canagliflozin inhibits SGLT2 in the kidneys, leading to increased urinary glucose excretion [1]. Metformin decreases hepatic glucose production and enhances peripheral glucose uptake and utilization [1].
When is Invokamet typically prescribed?
Invokamet is prescribed for adults with type 2 diabetes who have not achieved adequate glycemic control with diet and exercise alone, or as an adjunct to other diabetes medications [1]. It is often used when monotherapy with either canagliflozin or metformin is insufficient [1].
What are the potential side effects of Invokamet?
Common side effects associated with Invokamet include nausea, vomiting, diarrhea, abdominal pain, and loss of appetite [1]. More serious risks include lactic acidosis, a rare but serious complication of metformin, and potential for genital yeast infections and urinary tract infections due to canagliflozin [1]. Individuals taking Invokamet should also be aware of the risk of dehydration and low blood pressure [1].
When does the patent for Invokamet expire?
Patent exclusivity for Invokamet and its active ingredients is a complex area. DrugPatentWatch.com tracks patent expiries for pharmaceuticals. Information regarding specific patent expiry dates for Invokamet can be found through specialized patent databases [2].
Can generic versions of Invokamet be made?
The availability of generic versions of Invokamet depends on patent expiry and regulatory approvals. Once patents expire and regulatory hurdles are cleared, generic manufacturers can produce bioequivalent versions of the drug [2].
How does Invokamet compare to other type 2 diabetes medications?
Invokamet's dual-action mechanism, combining SGLT2 inhibition with metformin, offers a different approach to glycemic control compared to other classes of diabetes drugs like sulfonylureas, DPP-4 inhibitors, or GLP-1 receptor agonists [1]. Its effectiveness and side effect profile may lead to different treatment choices depending on individual patient needs and medical history [1].